

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 2004/000772

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/702, A61K 31/7056, A61P 29/00, A61P 3/10, A61P 9/10, A61P 11/06, A61P 19/02, A61P 19/04, 25/02, 25/28, 37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM ABS DATA, EPO-INTERNAL, WPI DATA, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02102384 A1 (ORTHOGENICS AS), 27 December 2002 (27.12.2002) --	1-7
X	WO 03007938 A1 (AIDAN, INC.), 30 January 2003 (30.01.2003) --	1-5,14-15
A	O'Sullivan J. et al.; "The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses"; Biochimica et Biophysica Acta 1647 (2003), 367-371. --	1-19
A	WO 03006003 A1 (BIOTIE THERAPIES CORPOATION), 23 January 2003 (23.01.2003) --	1-19

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 April 2005

Date of mailing of the international search report

25-04-2005

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Per Renström/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 2004/000772

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0202090 A2 (BIOTIE THERAPIES CORP.), 10 January 2002 (10.01.2002) --	1-19
A	WO 0238153 A1 (BIOVITRUM AB), 16 May 2002 (16.05.2002) -- -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI 2004/000772

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1 - 19
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI 2004/000772

Box II.2

Present claims 1-19 relate to use of an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found for only a very small proportion of these compounds.

Further, the expressions "useful as an agent capable of influencing an amine oxidase enzyme activity", "a disease or condition benefiting from inhibiting an amine oxidase enzyme", "inflammatory disease or condition", "a disease related to carbohydrate metabolism", "a disease related to aberrations in adipocyte differentiation or function or smooth muscle function" and "vascular disease" in claims 1, 5-6, 8, 10, 12 and 14 relate to a large and undefined number of different disorders which cannot be clearly defined by these expressions.

The application provides support for use of the compounds in the treatment of only a very limited number of such disorders. Moreover, in order to be considered clear according to Article 6 PCT, claims for second medical indications cannot be defined purely by the mechanism of action, but have to be limited to well-defined, practical applications in the form of specific pathological conditions.

Claims 1-19 do therefore not meet the requirements of Article 6 PCT that claims shall be clear, concise and supported by the description.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out only for those parts of the claims related to the aminoglycoside antibiotics shown in Scheme 1 (pages 13-15 of the description), in combination with the following medical conditions: different kinds of arthritis and joint diseases, vasculitis, Crohn's disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, Alzheimer's disease, pulmonary inflammatory disease, asthma, chronic obstructive pulmonary disease, dermatitis, psoriasis, diabetes, atherosclerosis, retinopathy, obesity, arteriosclerosis and ischemic heart disease. A general search of the VAP-1/SSAO inhibiting activity has been performed but cannot be considered complete regarding the various medical uses.

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/04/2005

International application No.

PCT/FI 2004/000772

WO	02102384	A1	27/12/2002	CA	2456685 A	27/12/2002
				EP	1401448 A	31/03/2004
				GB	0114672 D	00/00/0000
				US	20040236074 A	25/11/2004

WO	03007938	A1	30/01/2003	NONE		
----	----------	----	------------	------	--	--

WO	03006003	A1	23/01/2003	CA	2451569 A	23/01/2003
				HU	0401097 A	28/09/2004
				IL	159205 D	00/00/0000
				JP	2005501035 T	13/01/2005
				NO	20035139 D	00/00/0000
				US	20030125360 A	03/07/2003
				US	20040236108 A	25/11/2004
				ZA	200309112 A	23/07/2004

WO	0202090	A2	10/01/2002	AU	8216201 A	14/01/2002
				AU	8216301 A	14/01/2002
				CA	2414799 A	10/01/2002
				CA	2414807 A	10/01/2002
				CN	1450997 A,T	22/10/2003
				CN	1450998 A,T	22/10/2003
				EP	1301495 A	16/04/2003
				EP	1313718 A	28/05/2003
				HU	0301336 A	28/08/2003
				HU	0301625 A	28/11/2003
				IL	153766 D	00/00/0000
				IL	153767 D	00/00/0000
				JP	2004501962 T	22/01/2004
				JP	2004502682 T	29/01/2004
				NO	20026282 A	03/03/2003
				NO	20026283 A	28/02/2003
				NZ	523463 A	25/06/2004
				NZ	523464 A	31/10/2003
				PL	360353 A	06/09/2004
				PL	360374 A	06/09/2004
				US	6624202 B	23/09/2003
				US	20020173521 A	21/11/2002
				US	20040106654 A	03/06/2004
				WO	0202541 A	10/01/2002
				ZA	200300063 A	22/07/2003
				ZA	200300064 A	22/07/2003

WO	0238153	A1	16/05/2002	AU	1450502 A	21/05/2002
				SE	0004101 D	00/00/0000
				US	20020198189 A	26/12/2002
